AMLX
Amylyx Pharmaceuticals Inc
NASDAQ · Pharmaceuticals
$13.98
+0.99 (+7.62%)
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 140.81M | 449.35M | 403.13M | 461.04M |
| Net Income | -486,303,023 | 64.17M | 62.78M | 65.03M |
| EPS | — | — | — | — |
| Profit Margin | -345.4% | 14.3% | 15.6% | 14.1% |
| Rev Growth | +574.3% | +13.9% | +9.9% | +10.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 314.80M | 303.04M | 267.92M |
| Total Equity | — | 1.08B | 939.99M | 1.02B |
| D/E Ratio | — | 0.29 | 0.32 | 0.26 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -507,728,821 | 107.91M | 96.37M | 106.13M |
| Free Cash Flow | — | 81.20M | 53.03M | 80.72M |